Gene Expression of CSF3R/CD114 Is Associated with Poorer Patient Survival in Glioma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25053020 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Samir Ale Bark und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Principles of Surgery, Mackenzie Evangelical University, Curitiba 80730-000, PR, Brazil. Hauptthemen laut MEDLINE: Glioma, Glioblastoma, Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, The Center for Advanced Neurology and Neurosurgery (CEANNE), Mackenzie Evangelical University.
Abstract (Originalsprache)
Gliomas comprise most cases of central nervous system (CNS) tumors. Gliomas afflict both adults and children, and glioblastoma (GBM) in adults represents the clinically most important type of malignant brain cancer, with a very poor prognosis. The cell surface glycoprotein CD114, which is encoded by the CSF3R gene, acts as the receptor for the granulocyte colony stimulating factor (GCSF), and is thus also called GCSFR or CSFR. CD114 is a marker of cancer stem cells (CSCs), and its expression has been reported in several cancer types. In addition, CD114 may represent one among various cases where brain tumors hijack molecular mechanisms involved in neuronal survival and synaptic plasticity. Here, we describe CSF3R mRNA expression in human gliomas and their association with patient prognosis as assessed by overall survival (OS). We found that the levels of CSF3R/CD114 transcripts are higher in a few different types of gliomas, namely astrocytoma, pilocytic astrocytoma, and GBM, in comparison to non-tumoral neural tissue. We also observed that higher expression of CSF3R/CD114 in gliomas is associated with poorer outcome as measured by a shorter OS. Our findings provide early evidence suggesting that CSF3R/CD114 shows a potential role as a prognosis marker of OS in patients with GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Program in Principles of Surgery, Mackenzie Evangelical University, Curitiba 80730-000, PR, Brazil.
- The Center for Advanced Neurology and Neurosurgery (CEANNE), Porto Alegre 90560-010, RS, Brazil.
- InovAI Lab, nPITI/IMD, Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
- Bioinformatics Multidisciplinary Environment (BioME), Federal University of Rio Grande do Norte, Natal 59078-970, RN, Brazil.
- Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre 90035-003, RS, Brazil.
- Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre 90035-003, RS, Brazil.
ORCID-Profile: Rafael Roesler
Förderung
- National Council for Scientific and Technological Development
- The Center for Advanced Neurology and Neurosurgery (CEANNE)
- Mackenzie Evangelical University
- Children’s Cancer Institute (ICI)
Zitieren
APA
Bark, S. A., Dalmolin, M., Malafaia, O., Roesler, R., Fernandes, M. A. C., & Isolan, G. R. (2024). Gene Expression of CSF3R/CD114 Is Associated with Poorer Patient Survival in Glioma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25053020
Vancouver
Bark SA, Dalmolin M, Malafaia O, Roesler R, Fernandes MAC, Isolan GR. Gene Expression of CSF3R/CD114 Is Associated with Poorer Patient Survival in Glioma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25053020
BibTeX
@article{Bark2024,
author = {Bark, Samir Ale and Dalmolin, Matheus and Malafaia, Osvaldo and Roesler, Rafael and Fernandes, Marcelo A C and Isolan, Gustavo R},
title = {Gene Expression of CSF3R/CD114 Is Associated with Poorer Patient Survival in Glioma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25053020}
}
EUVIMED